Status:
COMPLETED
Diabetes Mellitus and Vulvovaginal Candidiasis
Lead Sponsor:
Indian Council of Medical Research
Conditions:
Diabetes Mellitus
Vulvovaginal Candidiasis
Eligibility:
FEMALE
18-66 years
Phase:
PHASE3
Brief Summary
Clinical and mycological response to oral fluconazole and boric acid suppositories was assessed in patients with diabetes mellitus and vulvovaginal candidiasis.
Detailed Description
A high proportion of vulvovaginal candidiasis is due to C.glabrata that responds poorly to fluconazole therapy. We assessed the clinical relief and mycological cure in response to oral fluconazole and...
Eligibility Criteria
Inclusion
- Consecutive patients with diabetes mellitus attending Endocrine OPD of All India Institute of Medical Sciences and in whom the diagnosis of vulvovaginal candidiasis was based on presence of clinical signs and symptoms and growth of Candida species on culture of high vaginal swab (HVS).
Exclusion
- Patients with vaginal discharge in whom Candida growth was not detected on fungal culture were excluded.
- Subjects also excluded were those with pregnancy,
- Sexually inactive girls,
- Age \> 65 years, renal failure and steroid therapy.
- Patients who did not give consent for pelvic examination,
- Those who were treated for any kind of vaginal discharge during the past three months and who did not comply with boric acid therapy or did not report on 15th day for repeat examination excluded.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00353561
Start Date
June 1 2004
End Date
April 1 2006
Last Update
May 22 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr Ravinder Goswami
Delhi, National Capital Territory of Delhi, India, 29